Abstract
CI-1000, a 9-deazaguanine analog, is an orally active and reversible inhibitor of purine nucleoside Phosphorylase (PNP). In vitro, CI-1000 inhibits human T-lymphoblast replication and the mixed lymphocyte response, as well as facilitating the intracellular accumulation of deoxyguanosine triphosphate (Gilbertsen et al., 1992; Dong and Gilbertsen, 1993; Wilburn et al. 1993). These changes are consistent with inhibition of PNP (Osborne and Scott, 1983; Fairbanks et al., 1990; Gilbertsen and Sircar, 1990) and the drug is approximately 10-fold more potent than a structurally related compound (Gilbertsen et al., 1991a, 1991b, and 1992).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Assenza, S.P., and Brown P.R., 1980, Comparison of high-performance liquid Chromatographic serum profiles of humans and dogs. J. Chromateg. 181:169–176.
Carson, D.A., Kaye, J., and Seegmiller J.E., 1978, Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J. Immunol. 121:1726–1731.
Dong. M.K., and Gilbertsen R.B., 1993, PD 141955 and CI-972: 9-Deazaguanine analog inhibitors of purine nucleoside Phosphorylase (PNP). II. Effects on nucleoside catabolism in human and rat blood in vitro. Agents Act. 39:C99–C101.
Fairbanks, L.D., Taddeo, A., Duley, J.A., and Simmonds, H.A., 1990, Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxyGTP in conditions simulating purine nucleoside Phosphorylase deficiency. J. Immunol. 144:485–491.
Frederick, D.L., Epstein, R.B., and Benear, J., 1985, Pharmacokinetics of 8-aminoguanosine. Clin. Chem. 31:939.
Giblet, E.R., Anderson, J.E., Cohen, F., Pollara, B., and Meuwissen, H.J., 1972, Adenosine-deaminase deficiency in two patients with impaired cellular immunity. Lancet 2:1067–1069.
Giblett, E.R. (1975). Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1:1010–1013.
Gilbertsen, R.B., Dong, M.K., Kossarek, L.M., Sircar, J.C., Kostlan, C.R., and Conroy, M.C., 1991a, Selective in vitro inhibition of human MOLT-4 lymphoblasts by the novel purine nucleoside Phosphorylase inhibitor, CI-972. Biochem. Biophys. Res. Comm. 178:1351–1358.
Gilbertsen, R.B., Dong, M.K., Wilburn, D.J., Kossarek, L.M., Sircar, J.C., Kostlan, C.R., and Conroy, M.C., Biochemical and pharmacologic properties of CI-972, a novel 9-deazaguanine analog purine nucleoside Phosphorylase (PNP) inhibitor, in: “Purine and Pyrimidine Metabolism in Man VII”. R.A. Harkness, G.B. Elion, and N. Zollner, editors. Plenum Press, New York, (1991b)
Gilbertsen, R.B. and Dong, M.K., 1985, Effects of 8-aminoguanosine, an inhibitor of purine nucleoside Phosphorylase, on plasma nucleosides in Wistar rats. Ann. N.Y. Acad. Sci. 451: 313–314.
Gilbertsen, R.B., U. Josyula, J.C. Sircar, M.K. Dong, W. Wu, DJ. Wilburn, and M.C. Conroy (1992). Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside Phosphorylase, CI-972 and PD 141955. Biochem Pharmacol. 44: 996–999.
Gilbertsen, R.B. and Sircar, J.C, Enzyme cascades: Purine metabolism and immunosuppression. in: “ Comprehensive Medicinal Chemistry, Volume 2”, C. Hansch, P.G. Sammes, and J.B. Taylor, editors. Pergamon Press, Oxford, (1990).
Hallak, H., Gilbertsen, R., Dong, M., and Guttendorf R., 1994, Phannakokinetic/pharmacodynamics of CI-1000, a purine nucleoside Phosphorylase (PNP) inhibitor, in rat and monkey. This Volume.
Kredich, N.M. and Hershfield, M.S., Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside Phosphorylase deficiency, in: “The Metabolic Basis of Inherited Disease, 6th Edition”. J.B. Stanbury, J.B. Wyngaarden, and D.S. Fredrickson, editors, McGraw-Hill, New York (1989).
Osborne, W.R.A. and Scott C.R., 1983, The metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T cell defect associated with purine nucleoside Phosphorylase deficiency. Biochemistry 214: 711–718.
Osborne, W.R.A., Deeg, H.J., and Slichter, S.J., 1986, A canine model of induced purine nucleoside Phosphorylase deficiency. Clin. Exp. Immunol. 66: 166–172.
Pickering, R.J., Pollara, B., and Meuwissen, H.J., 1974, Meeting Report: Workshop on severe combined immunological deficiency and adenosine deaminase deficiency. Clin. Immunol. Immunopath. 3: 301–303.
Rijksen, G., Kuis, W., Wadman, S.K., Spaapen, L.J.M., Duran, M., Voorbrood, B.S., Staal, G.E.J., Stoop, J.W., and Zegers, B.J.M., 1987, A new case of purine nucleoside Phosphorylase deficiency: Enzymologic, clinical, and immunologic characteristics. Pediatr. Res. 21: 137–141.
Sircar, J.C. and Gilbertsen, R.B., 1988, Purine nucleoside Phosphorylase (PNP) inhibitors: Potentially selective immunosuppressive agents. Drugs of the Future 13: 653–668.
Sircar, J.C. and Gilbertsen, R.B., 1990, Selective immunosuppressive agents. Drug News Perspect. 3: 213–217.
Staal, G.E., van Stoop, J.W., Zegers, B.J.M., Siegenbeek van Heukelom, L.H., van der Vlist, M.J.M., Wadman, S.K., and Martin, D.W., 1980, Erythrocyte metabolism in purine nucleoside Phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes. J. Clin. Invest. 65: 103–108.
Stoop, J.W., Zegers, B.J.M., Hendricks, G.F.M., Siegenbeek van Heukelom, L.H., Staal, G.E.J., de Bree, P.K., Wadman, S.K., and Ballieux R.E., 1977, Purine nucleoside Phosphorylase deficiency associated with selective cellular immunodeficiency. N. Engl. J. Med. 296: 651–655.
Wilburn, D.J., Dong, M.K., and Gilbertsen R.B., 1993, PD 141955 and CI-972: 9-Deazaguanine analog inhibitors of purine nucleoside Phosphorylase (PNP). I. Suppression of the human mixed lymphocyte reaction (MLR). Agents Act. 39: C96–C98.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Robertson, D.G., Urda, E.R., Bleavins, M.R., Lalwani, N.D. (1995). Changes in Monkey Plasma Purines Induced by Repeated Doses of CI-1000, a Novel Inhibitor of Purine Nucleoside Phosphorylase. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_38
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive